Alternatives to PAIN Act
- Bill Number
- S. 475
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-06: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-05-21T11:03:37Z
AI-Generated Summary
Purpose
The Alternatives to Prevent Addiction In the Nation Act (Alternatives to PAIN Act) aims to improve access to non-opioid drugs for managing pain under Medicare Part D, the program's prescription drug benefit. By reducing financial barriers and restrictions, it promotes non-addictive alternatives to opioids, helping to address the opioid crisis and prevent addiction among beneficiaries.
Key Provisions
- Definition of Qualifying Drugs: Qualifying non-opioid pain management drugs are those approved by the Food and Drug Administration (FDA) for reducing postoperative or acute pain, which do not interact with the body's opioid receptors, have no equivalent alternatives available in the U.S., and do not exceed a monthly cost threshold set by the Secretary of Health and Human Services (based on specialty-tier drug pricing).
- Cost-Sharing Adjustments (Effective January 1, 2026):
- No deductible applies to these drugs under Medicare Part D.
- These drugs must be placed on the lowest cost-sharing tier (e.g., the cheapest copay level) to minimize out-of-pocket costs for beneficiaries.
- Similar rules apply to low-income subsidy enrollees, ensuring they also face no deductible and minimal cost-sharing.
- Prohibitions on Utilization Management (Effective January 1, 2026):
- Prescription drug plans and Medicare Advantage plans with drug coverage (MA-PD plans) cannot require "step therapy" (a process forcing patients to try a preferred drug, like an opioid, before approving the non-opioid alternative).
- No "prior authorization" (pre-approval from the plan before the drug can be provided) is allowed for these drugs.
Significant Changes to Existing Law
- Amends Section 1860D-2 of the Social Security Act to add new rules exempting qualifying non-opioid drugs from deductibles and placing them on the lowest tier, building on existing cost-sharing protections (previously limited to other categories like insulin).
- Updates low-income subsidy provisions in Section 1860D-14 to extend these benefits consistently.
- Modifies Section 1860D-4 to ban step therapy and prior authorization specifically for these drugs, redesignating prior paragraphs and adding a new one; this expands beyond current limits on such practices for other medications.
- These changes apply only to plan years starting on or after January 1, 2026, allowing time for implementation.
Potential Impacts
- On Citizens (Medicare Beneficiaries): Seniors and people with disabilities enrolled in Part D will have easier, cheaper access to non-opioid pain relief for acute needs (e.g., after surgery), potentially reducing opioid prescriptions and addiction risks. This could lower overall healthcare costs for individuals by avoiding high deductibles or delays in care.
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) will need to oversee plan compliance, update guidance on cost thresholds, and monitor drug approvals, possibly increasing administrative workload but aligning with broader opioid reduction efforts.
- On International Relations: Minimal direct impact, though it may indirectly support U.S. public health initiatives that influence global pharmaceutical standards or opioid export/import policies.
- Broader effects include decreased opioid-related healthcare burdens (e.g., fewer overdoses or treatments), though it could slightly raise program costs if usage of these drugs increases.
Main Stakeholders Affected
- Medicare Part D Enrollees: Primary beneficiaries, especially those needing pain management for surgeries or injuries, gaining from reduced costs and barriers.
- Pharmaceutical Manufacturers: Producers of qualifying non-opioid drugs (e.g., certain biologics or alternatives like nerve blocks) may see increased demand and sales.
- Health Plans: Prescription drug plans (PDPs) and MA-PD plans must adjust formularies (drug lists) and processes, potentially facing higher short-term costs but avoiding opioid-related liabilities.
- Healthcare Providers: Doctors and pharmacists benefit from streamlined prescribing without insurance hurdles, enabling faster non-opioid treatments.
- Government: CMS and the Department of Health and Human Services enforce rules; taxpayers fund any net increase in Medicare spending.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens patient access rights under Medicare by limiting insurer restrictions, potentially setting precedents for future drug-specific exemptions. Relies on FDA approvals for definitions, ensuring evidence-based criteria without overregulating.
- Constitutional: No apparent conflicts; it operates within Congress's authority to regulate interstate commerce and social welfare programs like Medicare.
- Political: Bipartisan sponsorship (from 18 senators across parties) highlights consensus on combating the opioid epidemic. It advances national drug policy goals without mandating new funding, though implementation may spark debates on costs versus public health benefits.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (36)
Sen. Kelly, Mark [D-AZ], Sen. Capito, Shelley Moore [R-WV], Sen. Kaine, Tim [D-VA], Sen. Britt, Katie Boyd [R-AL], Sen. Shaheen, Jeanne [D-NH], Sen. Budd, Ted [R-NC], Sen. Coons, Christopher A. [D-DE], Sen. Cornyn, John [R-TX], Sen. Booker, Cory A. [D-NJ], Sen. Moran, Jerry [R-KS], Sen. Bennet, Michael F. [D-CO], Sen. Banks, Jim [R-IN], Sen. Padilla, Alex [D-CA], Sen. Daines, Steve [R-MT], Sen. Warner, Mark R. [D-VA], Sen. Hyde-Smith, Cindy [R-MS], Sen. Boozman, John [R-AR], Sen. Warnock, Raphael G. [D-GA], Sen. Justice, James C. [R-WV], Sen. Klobuchar, Amy [D-MN], Sen. Kennedy, John [R-LA], Sen. Cortez Masto, Catherine [D-NV], Sen. Blackburn, Marsha [R-TN], Sen. Gallego, Ruben [D-AZ], Sen. King, Angus S., Jr. [I-ME], Sen. Ossoff, Jon [D-GA], Sen. Merkley, Jeff [D-OR], Sen. Sheehy, Tim [R-MT], Sen. Fischer, Deb [R-NE], Sen. Schiff, Adam B. [D-CA], Sen. Blumenthal, Richard [D-CT], Sen. Husted, Jon [R-OH], Sen. Duckworth, Tammy [D-IL], Sen. Marshall, Roger [R-KS], Sen. McCormick, David [R-PA], Sen. Hirono, Mazie K. [D-HI]
Recent Actions
- 2025-02-06: Read twice and referred to the Committee on Finance.
- 2025-02-06: Introduced in Senate
Bill Versions
- Alternatives to Prevent Addiction In the Nation Act — issued 2025-02-06 — PDF (6 pages)